J2 Capital Management Inc Invests $397,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

J2 Capital Management Inc purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 4,068 shares of the medical equipment provider's stock, valued at approximately $397,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Janus Henderson Group PLC grew its position in Lantheus by 72.7% during the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock worth $554,583,000 after buying an additional 2,610,118 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in shares of Lantheus by 79.9% in the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock worth $475,590,000 after acquiring an additional 2,361,000 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in Lantheus by 40.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock worth $135,025,000 after purchasing an additional 435,445 shares during the last quarter. Raymond James Financial Inc. bought a new position in Lantheus in the 4th quarter worth approximately $36,183,000. Finally, Keybank National Association OH bought a new position in Lantheus in the 4th quarter worth approximately $27,526,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Lantheus

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. This represents a 8.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.50% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have commented on LNTH shares. Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. B. Riley reduced their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. Finally, Truist Financial reduced their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Lantheus presently has a consensus rating of "Buy" and an average price target of $132.67.

Lantheus Stock Up 2.1%

Shares of LNTH stock traded up $1.57 on Monday, reaching $77.13. The stock had a trading volume of 1,077,554 shares, compared to its average volume of 992,559. The firm's 50-day moving average is $92.07 and its two-hundred day moving average is $91.81. The firm has a market capitalization of $5.34 billion, a price-to-earnings ratio of 12.83 and a beta of 0.23. Lantheus Holdings, Inc. has a 12 month low of $73.11 and a 12 month high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The firm had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm's revenue for the quarter was up .8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.69 earnings per share. On average, sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.